Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
CME ACTIVITY - Dispatch

Natural History of and Dynamic Changes in Clinical Manifestation, Serology, and Treatment of Brucellosis, China

Hongyu Wang1, Hongyan Liu1, Qiran Zhang1, Xiaobo Lu1, Dan Li1, Haocheng Zhang1, Yan A. Wang, Rongjiong Zheng, Yi Zhang, Zhangfan Fu, Ke Lin, Chao Qiu, Yan O. Wang, Ye GuComments to Author , Jingwen AiComments to Author , and Wenhong ZhangComments to Author 
Author affiliations: National Medical Center for Infectious Disease, National Clinical Research Center for Aging and Medicine, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, China (H. Wang, Q. Zhang, H. Zhang, Y. Zhang, Z. Fu, K. Lin, C. Qiu, J. Ai, W. Zhang); The Sixth People’s Hospital of Shenyang, Shenyang, China (H. Liu, D. Li, Y.A. Wang, Y.O. Wang, Y. Gu); Emergency Treatment and Innovation Center of Public Health Emergencies, Shenyang (H. Liu, D. Li, Y.A. Wang, Y.O. Wang, Y. Gu); Center for Infectious Diseases, the First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, China (X. Lu, R. Zheng); Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai (W. Zhang)

Main Article

Figure 2

Dynamic characteristics of serum agglutination test and treatment courses in case-patients with brucellosis, China, 2014–2020. A) Seroconversion after treatment initiation; B) serum agglutination test titer distribution at baseline and 180 days after treatment initiation; C) treatment length of case-patients without systemic involvement; D) possible reasons for lengthened treatment in brucellosis case-patients without systemic involvement.

Figure 2. Dynamic characteristics of serum agglutination test and treatment courses in case-patients with brucellosis, China, 2014–2020. A) Seroconversion after treatment initiation; B) serum agglutination test titer distribution at baseline and 180 days after treatment initiation; C) treatment length of case-patients without systemic involvement; D) possible reasons for lengthened treatment in brucellosis case-patients without systemic involvement.

Main Article

1These authors contributed equally to this article.

Page created: May 12, 2022
Page updated: June 21, 2022
Page reviewed: June 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external